Skip to main content

  • Low-Dose DCB Prevails; ViV TAVR at 3 Years; LDL vs Lesion Stability

    • Posted: 05/31/2019
    • Author:

      Nicole Lou, Reporter, MedPage Today/CRTonline.org

    • 2019News Articles

    Interventional cardiology news to note

    The Stellarex low-dose drug-coated balloon showed safety and efficacy out to 3 years in the ILLUMENATE pivotal trial and the ILLUMENATE European trial. Mortality rates of 10.1% and 9.4%, respectively, didn't differ significantly from uncoated balloon control groups, according to Philips.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details